Study explores atezolizumab for myelodysplastic syndrome
FDA approval may come in 2019
Lower toxicity than conventional chemo
New recommendations for second-line therapy
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Doctors called to heal, not just treat
Groundbreaking study paves way for targeted therapy
Rationale and status reports on mechanistically diverse strategies
Gene signatures differentiate clinical response
10-year outcomes favor autologous over implant
Initial study results are encouraging
Advertisement
Advertisement